ライフサイエンスコーパス: inclusion body myositis

1 uld be a favourable approach to treatment of inclusion body myositis.

2 otoxic T lymphocyte-mediated autoimmunity in inclusion body myositis.

3 d 2010 Medical Research Council criteria for inclusion body myositis.

4 itis or dermatomyositis, and 2 families with inclusion body myositis.

5 A alterations may be accelerated in sporadic inclusion body myositis.

6 group demonstrated histological features of inclusion body myositis.

7 proposed criteria for definite and possible inclusion body myositis.

8 stological confirmation may nonetheless have inclusion body myositis.

9 ntotemporal lobar degeneration, and sporadic inclusion body myositis.

10 scles, quadriceps, and ankle dorsiflexors in inclusion body myositis.

11 cceptable safety profile in individuals with inclusion body myositis.

12 , and efficacy of arimoclomol in people with inclusion body myositis.

13 l (3.3%, 1.8-4.9, p=0.0007) in patients with inclusion body myositis.

14 ly definite by MRC criteria was required for inclusion body myositis.

15 genotype confers the highest disease risk in inclusion body myositis.

16 r focus on polymyositis, dermatomyositis and inclusion body myositis.

17 mulate intracellularly in some patients with inclusion body myositis.

18 includes polymyositis, dermatomyositis, and inclusion body myositis.

19 omprising dermatomyositis, polymyositis, and inclusion body myositis.

20 sent key early events in the pathogenesis of inclusion body myositis.

21 s are potential disease activity sensors for inclusion body myositis.

22 uman monoclonal antibody-in individuals with inclusion body myositis.

23 vided into dermatomyositis, polymyositis and inclusion body myositis.

24 ive muscle disease of aging humans, sporadic inclusion body myositis.

25 ulates early in Alzheimer's disease (AD) and inclusion body myositis.

26 thies are polymyositis, dermatomyositis, and inclusion body myositis.

27 muscle fibers that are specific to sporadic inclusion-body myositis.

28 e new avenues toward the therapy of sporadic inclusion-body myositis.

29 slightly to muscle fiber damage in sporadic inclusion-body myositis.

30 subsets: dermatomyositis, polymyositis, and inclusion-body myositis.

31 ortant clues to the pathogenesis of sporadic inclusion-body myositis.

32 ent concepts of the pathogenesis of sporadic inclusion-body myositis.

33 myopathy, polymyositis, dermatomyositis, and inclusion body myositis].

34 Inclusion body myositis, a chronic inflammatory disorder

35 tal muscle biopsies taken from patients with inclusion body myositis, a degenerative disorder in whic

36 individual cells from patients with sporadic inclusion body myositis, a late-onset inflammatory myopa

37 Muscle biopsies from patients with sporadic inclusion body myositis, a well defined myopathy with ch

38 likely that genetic muscular dystrophies and inclusion body myositis account for some cases of appare

39 There are candidate treatments for inclusion body myositis and a need for additional double

40 retin Val122Ile allele who has both sporadic inclusion body myositis and cardiac amyloidosis.

41 in scattered muscle fibers occur in sporadic inclusion body myositis and clinically similar disorders

42 of mtDNA deletions in patients with sporadic inclusion body myositis and control subjects, mtDNA alte

43 predicted the presence of dendritic cells in inclusion body myositis and of an IFN-alpha/beta respons

44 tically significant benefit in patients with inclusion body myositis and paraproteinemic anti-myelin-

45 Dendritic cells present in inclusion body myositis and polymyositis are primarily m

46 Although inclusion body myositis and polymyositis have been chara

47 ed intramuscular Ag-specific autoimmunity in inclusion body myositis and polymyositis.

48 ociated through genetic analyses to sporadic inclusion body myositis and sarcoidosis.

49 trials in dermatomyositis, polymyositis, and inclusion body myositis and suggests an approach to trea

50 FOR A SCIENTIFIC COMMENTARY ON THIS ARTICLE: Inclusion body myositis and T cell large granular lympho

51 Sporadic inclusion body myositis and the hereditary inclusion bod

52 ripheral neuropathy were also more common in inclusion body myositis and unresponsive polymyositis th

53 d knee extensor involvement was specific for inclusion body myositis and unresponsive polymyositis.

54 y provides insights into the pathogenesis of inclusion-body myositis and concludes that in sIBM one s

55 cell activation in polymyositis and sporadic inclusion-body myositis and the cause of vacuolar degene

56 cot-Marie-Tooth disease 1A, 20 patients with inclusion body myositis, and 29 healthy controls (alloca

57 domised controlled trial done in people with inclusion body myositis, and it provides important natur

58 fibers are common in patients with sporadic inclusion body myositis, and multiple [correction of mut

59 o the disease mechanisms of dermatomyositis, inclusion body myositis, and polymyositis gained from la

60 in muscle in patients with dermatomyositis, inclusion body myositis, and polymyositis.

61 quences of genes that predispose to sporadic inclusion-body myositis, and of human muscle fiber aging

62 In polymyositis and sporadic inclusion-body myositis, antigen-specific and clonally e

63 e diseases dermatomyositis, polymyositis and inclusion body myositis are of unknown cause, but immune

64 The causes of inclusion body myositis are still unknown.

65 forms are polymyositis, dermatomyositis, and inclusion body myositis) are systemic autoimmune disease

66 itochondrial pathology (IM-VAMP), which have inclusion body myositis as a pathologic subtype and are

67 d an increase in KLRG1 expressing T cells in inclusion body myositis blood.

68 le, relative to placebo, in individuals with inclusion body myositis but did not improve 6MWD.

69 pect that patients with clinical features of inclusion body myositis but lacking histological confirm

70 arison to other mimicking diagnoses, such as inclusion body myositis, cervical or lumbar radiculopath

71 odel performance on cohorts of patients with inclusion body myositis, cervical radiculopathy, lumbar

72 In polymyositis and sporadic inclusion body myositis, clonal expansion of CD8+ cells

73 In polymyositis and inclusion-body myositis, clonally expanded CD8-positive

74 of the vacuolated muscle fibers of sporadic inclusion body myositis contained well-defined, strongly

75 nd eight studies using various treatments in inclusion body myositis did not show benefit.

76 inclusion-body myositis muscle biopsies with inclusion-body myositis experimental models in tissue cu

77 , we prospectively screened 38 patients with inclusion body myositis for the presence of expanded lar

78 Ultrasound has the ability to differentiate inclusion body myositis from other myopathies.

79 The most important feature distinguishing inclusion body myositis from the other two inflammatory

80 that characterize polymyositis and sporadic inclusion-body myositis from the non-specific, secondary

81 Inclusion body myositis, from its origins 30 years ago,

82 Eligible participants had a diagnosis of inclusion body myositis fulfilling the European Neuromus

83 the change from baseline to month 20 in the Inclusion Body Myositis Functional Rating Scale (IBMFRS)

84 elated with the lower limb components of the inclusion body myositis functional rating score (rho=-0.

85 Most (22/38; 58%) patients with inclusion body myositis had aberrant populations of larg

86 Interest in sporadic inclusion-body myositis has been enhanced by the recent

87 Although most patients with inclusion body myositis have characteristic muscle biops

88 tained muscle biopsy specimens from sporadic inclusion body myositis, hereditary inclusion body myopa

89 Compared with sporadic inclusion body myositis, however, in which the T-cell re

90 histologically distinct patient populations, inclusion body myositis (IBM) and anti-Jo-1-associated m

91 inst a 43 kDa muscle autoantigen in sporadic inclusion body myositis (IBM) and demonstrated the feasi

92 Some of these features are shared with inclusion body myositis (IBM) and this entity cannot be

93 Historically, the diagnosis of sporadic inclusion body myositis (IBM) has required the demonstra

94 Inclusion body myositis (IBM) is a poorly understood aut

95 PURPOSE OF REVIEW: Inclusion body myositis (IBM) is a poorly understood pro

96 Inclusion body myositis (IBM) is an inflammatory muscle

97 Inclusion body myositis (IBM) is an inflammatory myopath

98 Inclusion body myositis (IBM) is an inflammatory myopath

99 ted muscle cells or markers of cell death in inclusion body myositis (IBM) is in distinction to the s

100 Inclusion body myositis (IBM) is often viewed as an enig

101 Sporadic inclusion body myositis (IBM) is the most common acquire

102 Inclusion body myositis (IBM) is the most common muscle

103 IM, their effectiveness for individuals with inclusion body myositis (IBM) remains uncertain.

104 Serum from 70 patients with sporadic inclusion body myositis (IBM) was subjected to agarose g

105 Inclusion body myositis (IBM), a degenerative and inflam

106 New candidate genes have been examined in inclusion body myositis (IBM), and a novel gene transfer

107 polymyositis (PM), dermatomyositis (DM), and inclusion body myositis (IBM), diseases that result from

108 om muscle biopsies of patients with sporadic inclusion body myositis (IBM), immune-mediated necrotizi

109 To examine new developments in sporadic inclusion body myositis (IBM), including updated clinica

110 ith dermatomyositis (DM), polymyositis (PM), inclusion body myositis (IBM), myasthenia gravis, or gen

111 scle wasting in Alzheimer's disease (AD) and inclusion body myositis (IBM), respectively.

112 t molecular similarities between PM-Mito and inclusion body myositis (IBM), suggesting a trajectory f

113 The pathogenic basis of inclusion body myositis (IBM), the leading muscle degene

114 Inclusion body myositis (IBM), the most common age-relat

115 Inclusion body myositis (IBM), the most common muscle di

116 nosis and treatment persist, particularly in inclusion body myositis (IBM), where no effective therap

117 e consistent histologic findings in sporadic inclusion body myositis (IBM).

118 aimed to elucidate the molecular features of inclusion body myositis (IBM).

119 genesis, diagnosis and treatment of sporadic inclusion body myositis (IBM).

120 arget of serum antibodies from patients with inclusion body myositis (IBM).

121 reatment and serum and imaging biomarkers of inclusion body myositis (IBM).

122 fications: dermatomyositis, polymyositis and inclusion body myositis (IBM).

123 eneration in myositis, focusing primarily on inclusion body myositis (IBM).

124 ease (AD) brain, vacuolated muscle fibers of inclusion-body myositis (IBM) contain abnormally accumul

125 Sporadic inclusion-body myositis (IBM) is the most common muscle

126 are an important diagnostic criterion of the inclusion-body myositis (IBM) muscle biopsy; but, until

127 egulated kinase (ERK) in the pathogenesis of inclusion-body myositis (IBM) was investigated by immuno

128 e describe the occurrence of an inflammatory inclusion body myositis in siblings of a single generati

129 yositis, reduced key pathological markers of inclusion body myositis in two in-vitro models represent

130 , s-IBM can also occur in families (familial inclusion body myositis), in a pattern analogous to the

131 Sporadic inclusion body myositis is a frequent, acquired, adult-o

132 Inclusion body myositis is a late onset treatment-refrac

133 Inclusion body myositis is an idiopathic inflammatory my

134 Inclusion body myositis is much less responsive to immun

135 Inclusion body myositis is the most common progressive m

136 Although the cause of sporadic inclusion body myositis is unknown, GNE myopathy is asso

137 structs coding for the Alzheimer disease and inclusion body myositis-linked beta-amyloid precursor pr

138 Typical of sporadic inclusion body myositis muscle biopsies are vacuolated m

139 The extent of CD8+ and CD57+ cells in inclusion body myositis muscle correlated with the size

140 tified a signature of T-cell cytotoxicity in inclusion body myositis muscle coupled with a signature

141 entified the presence of KLRG1 on pathogenic inclusion body myositis muscle invading T cells and an i

142 We examined inclusion body myositis muscle T-cell proliferation by K

143 ritic cells are abundant in polymyositis and inclusion body myositis muscle.

144 equences, and correlate findings in sporadic inclusion-body myositis muscle biopsies with inclusion-b

145 he recent identification within the sporadic inclusion-body myositis muscle fibers of several abnorma

146 ent may only slightly contribute to sporadic inclusion-body myositis muscle-fiber damage.

147 In polymyositis and inclusion body myositis, muscle fibers are surrounded an

148 ata on 411 muscle samples from patients with inclusion body myositis (n = 40), other muscle diseases

149 In all control and inclusion body myositis or myopathy biopsy specimens, Ap

150 nsubstantiated benefit in some patients with inclusion-body myositis, paraproteinemic IgM demyelinati

151 nflammatory responses that resemble sporadic inclusion body myositis pathology.

152 Here, we report on translational studies of inclusion body myositis patient muscle compared with a d

153 ge granular lymphocytes into muscle in 15/15 inclusion body myositis patients but in only 1/28 patien

154 s that accumulate in the myocyte vacuoles of inclusion body myositis patients.

155 drome, immune-mediated necrotizing myopathy, inclusion body myositis, polymyositis and overlap myosit

156 drome, immune-mediated necrotizing myopathy, inclusion body myositis, polymyositis and overlap myosit

157 Inclusion body myositis, polymyositis, and dermatomyosit

158 s of 46 patients newly diagnosed with either inclusion body myositis, polymyositis, or dermatomyositi

159 een reported to be elevated in patients with inclusion-body myositis, polymyositis, dermatomyositis,

160 ne of the largest trials done in people with inclusion body myositis, providing data on disease progr

161 safe and well-tolerated in a pilot study of inclusion body myositis, reduced key pathological marker

162 e cause of vacuolar degeneration in sporadic inclusion-body myositis remain unclear.

163 Treatment of sporadic inclusion-body myositis remains a challenge.

164 opathies (dermatomyositis, polymyositis, and inclusion body myositis) remains obscure.

165 Sporadic inclusion body myositis (s-IBM) is a chronic inflammator

166 , are the characteristic feature of sporadic inclusion body myositis (s-IBM) muscle biopsies, we stud

167 eficiency virus infection (HIV-PM), sporadic inclusion body myositis (s-IBM), dermatomyositis (DM), a

168 atients have a disease identical to sporadic inclusion body myositis (s-IBM).

169 Sporadic inclusion-body myositis (s-IBM) and hereditary inclusion

170 seeking the pathogenic mechanism of sporadic inclusion-body myositis (s-IBM) and hereditary inclusion

171 Sporadic inclusion-body myositis (s-IBM) is the most common progr

172 The hallmark pathologies of sporadic inclusion-body myositis (s-IBM) muscle fibers are autoph

173 in-aggregates are characteristic of sporadic inclusion-body myositis (s-IBM) muscle fibers.

174 ause in the muscle of patients with sporadic inclusion body myositis (sIBM) clonally expanded CD8+ T

175 Sporadic inclusion body myositis (sIBM) is a poorly understood im

176 Sporadic inclusion body myositis (sIBM) is an idiopathic inflamma

177 Sporadic inclusion body myositis (sIBM) is an inflammatory myopat

178 Sporadic Inclusion Body Myositis (sIBM) is the most common acquir

179 the muscle fibers of patients with sporadic inclusion body myositis (sIBM) is unknown.

180 Sporadic inclusion body myositis (sIBM) pathogenesis is unknown;

181 TAR DNA binding protein TDP-43, in sporadic inclusion body myositis (sIBM) sarcoplasm are important

182 myositis (DM) who improved and patients with inclusion body myositis (sIBM) who did not improve after

183 Sporadic inclusion body myositis (sIBM), a common adult-onset myo

184 of the skeletal muscle pathology in sporadic inclusion body myositis (sIBM), have remained elusive.

185 PM), Necrotizing Myositis (NM), and sporadic Inclusion Body Myositis (sIBM).

186 in the pathogenesis of familial and sporadic inclusion body myositis (sIBM).

187 Sporadic inclusion-body myositis (sIBM) is the most common disabl

188 ions, including muscular dystrophy, sporadic inclusion body myositis, spinal muscular atrophy, cachex

189 eta-analysis of the apolipoprotein E gene in inclusion body myositis suggests that this gene does not

190 In sporadic inclusion-body myositis the inflammatory cells invade no

191 In many patients with inclusion body myositis, the autoimmune T cell expansion

192 In inclusion body myositis, the HLA 8.1 ancestral haplotype

193 ciated with aging and is related to sporadic inclusion body myositis, the most common acquired muscle

194 Inclusion body myositis, the most common muscle disorder

195 In conceptualizing a treatment for sporadic inclusion-body myositis, the accumulations of amyloid-be

196 Sporadic inclusion-body myositis, the most common muscle disease

197 Sporadic inclusion-body myositis, the most common muscle disease

198 .3]) and MTR reduced compared with controls (inclusion body myositis thigh -1.5 percentage units [pu;

199 ared with controls (regression coefficients: inclusion body myositis thigh 4.0 ms [SE 0.5], calf 3.5

200 We studied 56 patients with sporadic inclusion body myositis, using a combination of clinical

201 In inclusion-body myositis, vacuolar formation with amyloid

202 2017 and May 22, 2019, 152 participants with inclusion body myositis were randomly assigned to arimoc

203 Inclusion body myositis, which now appears to be the mos

204 ith either Charcot-Marie-Tooth disease 1A or inclusion body myositis who were attending the inherited